Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive kidney disease registry aims to uncover best treatments

NCT ID NCT07481526

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This observational study will follow 3,000 Chinese adults with chronic kidney disease (CKD) to see how they are treated in real-world clinics and what happens to their health over time. Researchers will track medications, kidney function, heart risks, and hospital visits. The goal is to better understand current care patterns and improve future treatment strategies for CKD patients in China.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal which treatments work best for Chinese CKD patients, helping doctors make more informed decisions.
What could go wrong
This is an observational study, not a treatment trial. It collects data but does not test any new drug, so it cannot directly lead to a cure or new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult CKD patients who meet the eligibility criteria

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged ≥18 years. * Willing and able to provide written informed consent to participate in the study. * Confirmed CKD diagnosis at enrolment, defined by at least one of the following: * eGFR \<60 mL/min/1.73 m² for ≥3 months, OR * Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months Exclusion Criteria: * Having a life-threatening comorbidity with life expectancy \< 2 years. * Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months. * Pregnant or breastfeeding women. * Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment. * Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    59 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Anning, Yunnan - South Region, China

  • Research Site

    RECRUITING

    Beijing, Beijing, China

  • Research Site

    RECRUITING

    Cangzhou, Hebei - North Region, China

  • Research Site

    RECRUITING

    Caoxian County, Shandong Province, China

  • Research Site

    RECRUITING

    Changzhou, Jiangsu Province, China

  • Research Site

    RECRUITING

    Chengdu, Sichuan Province, China

  • Research Site

    RECRUITING

    Chongqing, Chongqing, China

  • Research Site

    RECRUITING

    Chongqing, Sichuan Province, China

  • Research Site

    NOT_YET_RECRUITING

    Dalian, Liaoning, China

  • Research Site

    RECRUITING

    Dongguan, Guangdong, China

  • Research Site

    RECRUITING

    Foshan, Guangdong, China

  • Research Site

    RECRUITING

    Fuzhou, Fujian, China

  • Research Site

    RECRUITING

    Ganzhou, Jiangxi, China

  • Research Site

    RECRUITING

    Guangzhou, Guangdong, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

  • Research Site

    RECRUITING

    Guiyang, Guizhou, China

  • Research Site

    RECRUITING

    Hangzhou, Zhejiang, China

  • Research Site

    RECRUITING

    Harbin, Heilongjiang, China

  • Research Site

    NOT_YET_RECRUITING

    Hohhot, Inner Mongolia, China

  • Research Site

    RECRUITING

    Huai An, Jiangsu Province, China

  • Research Site

    RECRUITING

    Jiaozuo, Henan Province, China

  • Research Site

    RECRUITING

    Jinan, Shandong Province, China

  • Research Site

    RECRUITING

    Jining, Shandong Province, China

  • Research Site

    RECRUITING

    Jiujiang, Jiangxi, China

  • Research Site

    RECRUITING

    Kunming, Yunnan, China

  • Research Site

    RECRUITING

    Nanchang, Jiangxi, China

  • Research Site

    RECRUITING

    Nanjing, Jiangsu Province, China

  • Research Site

    RECRUITING

    Nanning, Guangxi, China

  • Research Site

    RECRUITING

    Nanping, Fujian, China

  • Research Site

    RECRUITING

    Nantong, Jiangsu Province, China

  • Research Site

    RECRUITING

    Nanyang, Henan Province, China

  • Research Site

    RECRUITING

    Shanghai, Shanghai, China

  • Research Site

    RECRUITING

    Shangqiu, Henan Province, China

  • Research Site

    RECRUITING

    Shantou, Guangdong, China

  • Research Site

    RECRUITING

    Shaoxing, Zhejiang, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, Liaoning, China

  • Research Site

    RECRUITING

    Shenzhen, Guangdong, China

  • Research Site

    RECRUITING

    Shijiazhuang, Hebei, China

  • Research Site

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, China

  • Research Site

    RECRUITING

    Suzhou, Jiangsu Province, China

  • Research Site

    RECRUITING

    Taiyuan, Shanxi, China

  • Research Site

    RECRUITING

    Taizhou, Jiangsu, China

  • Research Site

    RECRUITING

    Tianjin, Tianjin, China

  • Research Site

    RECRUITING

    Tonglu County, Zhejiang, China

  • Research Site

    RECRUITING

    Urumqi, Xinjiang, China

  • Research Site

    RECRUITING

    Weifang, Shandong Province, China

  • Research Site

    RECRUITING

    Wuhan, Hubei, China

  • Research Site

    RECRUITING

    XI An, Shaanxi Province, China

  • Research Site

    RECRUITING

    Xiamen, Fujian, China

  • Research Site

    RECRUITING

    Xiangyang, Hubei, China

  • Research Site

    RECRUITING

    Xiantao, Hubei, China

  • Research Site

    RECRUITING

    Xuancheng, Anhui, China

  • Research Site

    RECRUITING

    Yinchuan, Ningxia Hui Autonomous Region, China

  • Research Site

    RECRUITING

    Yiwu,Zhejiang, China

  • Research Site

    RECRUITING

    Zhangzhou, Fujian, China

  • Research Site

    RECRUITING

    Zhenjiang, Jiangsu Province, China

  • Research Site

    RECRUITING

    Zhoushan, Zhejiang, China

  • Research Site

    RECRUITING

    Zhuji, Zhejiang, China

  • Research Site

    RECRUITING

    Zibo, Shandong Province, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.